Evidence map›Paper›PMID 32772903›Full record

ArticleRegenerative medicine2020

Delivery of hepatocyte growth factor mRNA from nanofibrillar scaffolds in a pig model of peripheral arterial disease.

Tatiana S Zaitseva, Guang Yang, Dimitris Dionyssiou, Maedeh Zamani, Steve Sawamura, Eduard Yakubov, James Ferguson, Richard L Hallett, Dominik Fleischmann, Michael V Paukshto and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Regenerative medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Bioengineering Cell Therapy for Treatment of Peripheral Artery Disease.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Review
  4. Matrices Activated with Messenger RNA.Journal of functional biomaterials · 2023
    Review
  5. Extracellular Matrix-Based Biomaterials for Cardiovascular Tissue Engineering.Journal of cardiovascular development and disease · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Tatiana S ZaitsevaFibralign Corporation, Union City, CA 94587, USA.
Guang YangStanford Cardiovascular Institute, Stanford, CA 94305, USA.
Dimitris DionyssiouFibralign Corporation, Union City, CA 94587, USA.
Maedeh ZamaniStanford Cardiovascular Institute, Stanford, CA 94305, USA.
Steve SawamuraFibralign Corporation, Union City, CA 94587, USA.
Eduard YakubovPhaRNA, LLC, Houston, TX 77024, USA.
James FergusonPalo Alto Bioresources, Berkeley, CA 94705, USA.
Richard L HallettStanford Cardiovascular Institute, Stanford, CA 94305, USA.
Dominik FleischmannStanford Cardiovascular Institute, Stanford, CA 94305, USA.
Michael V PaukshtoFibralign Corporation, Union City, CA 94587, USA.
Ngan F HuangStanford Cardiovascular Institute, Stanford, CA 94305, USA.ORCID 0000-0003-2298-6790
Cardiovascular Institute of the South · USFibralign (United States) · USVA Palo Alto Health Care System · USAristotle University of Thessaloniki · GRSylvana Research · US

Funding

Aligned Nanofibrillar Scaffolds Enhance Angiogenesis and Viability in Ischemia: Sex Differences Administrative SupplementR01HL127113 · NHLBI · STANFORD UNIVERSITY · PI HUANG, NGAN F. · 2016 to 2020
$2.5M
Engineered matrix microarrays to enhance the regenerative potential of iPSC-derived endothelial cellsR01HL142718 · NHLBI · STANFORD UNIVERSITY · PI HEILSHORN, SARAH C, HUANG, NGAN F. · 2018 to 2021
$1.6M
PROVIDE RABBITS, RATS, IMCE, HAMSTERS, GERBILS, AND GUINEA PIGS27307C0009 · NIEHS · PI MARSION, LESLIE · 2007 to 2007
$540k
Vascularized Cardiac Patch with Physiological Orientation for Myocardial RepairI01BX002310 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI HUANG, NGAN F. · 2015 to 2018
–
Engineering Vascularized Skeletal Muscle for Treatment of Volumetric Muscle LossI01BX004259 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI Ngan F. Huang · 2019 to 2026
–
BLRD VA I01 BX002310BLRD VA I01 BX004259NHLBI NIH HHS R01 HL127113NHLBI NIH HHS R01 HL142718NIEHS NIH HHS 27307C0009
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Disease Models, AnimalAnimalsCollagenHepatocyte Growth FactorHindlimbIschemiaPeripheral Arterial DiseaseRNA, MessengerSwineTissue ScaffoldsCollagenHepatocyte Growth FactorRNA, Messengerbiomaterialsextracellular matrixgene deliverymodified mRNAnanofibrillar scaffold

Identifiers

PMID32772903
PMCPMC7787177
OpenAlexW3048959657

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.